{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:30:38Z","timestamp":1767375038796},"reference-count":87,"publisher":"Frontline Medical Communications, Inc.","issue":"4","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cutaneous Medicine and Surgery"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.sder.2006.08.004","type":"journal-article","created":{"date-parts":[[2006,12,15]],"date-time":"2006-12-15T12:27:38Z","timestamp":1166185658000},"page":"207-220","source":"Crossref","is-referenced-by-count":15,"title":["Update on Connective Tissue Diseases in Dermatology"],"prefix":"10.12788","volume":"25","author":[{"given":"Melissa I.","family":"Costner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee H.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","reference":[{"key":"10.1016\/j.sder.2006.08.004_bib1","first-page":"820","article-title":"A comparison of prospective and retrospective evaluations of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index for systemic lupus erythematosus","volume":"32","author":"Bernatsky","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib2","series-title":"Cutaneous Manifestations of Rheumatic Diseases","author":"Sontheimer","year":"2004"},{"key":"10.1016\/j.sder.2006.08.004_bib3","doi-asserted-by":"crossref","unstructured":"Ting W, Stone MS, Racila D, et al: Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus 13:941-950, 04","DOI":"10.1191\/0961203304lu2037sa"},{"key":"10.1016\/j.sder.2006.08.004_bib4","doi-asserted-by":"crossref","unstructured":"Callen J: Collagen vascular diseases. J Am Acad Dermatol 51:427-439, 04","DOI":"10.1016\/j.jaad.2004.04.007"},{"key":"10.1016\/j.sder.2006.08.004_bib5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.11206","article-title":"Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis","volume":"49","author":"Alexiades-Armenakas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/j.1365-2133.2005.06784.x","article-title":"Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA","volume":"153","author":"Wenzel","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1191\/096120399678847632","article-title":"Chilblain\u2019s lupus erythematosus is associated with antibodies to SSA\/Ro","volume":"8","author":"Franceschini","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.sder.2006.08.004_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00005792-200105000-00004","article-title":"Clinical and histopathologic features and immunologic variables in patients with severe chilblains","volume":"80","author":"Viguier","year":"2001","journal-title":"Medicine"},{"key":"10.1016\/j.sder.2006.08.004_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10067-004-1024-2","article-title":"Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C","volume":"24","author":"Niewold","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib10","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/art.11226","article-title":"Interferon alpha-a new target for therapy in SLE","volume":"48","author":"Crow","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib11","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sder.2006.08.004_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/ar1888","article-title":"Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus","volume":"8","author":"Lenert","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.sder.2006.08.004_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1681\/ASN.2005070714","article-title":"Toll-like receptor-7 modulates immune complex glomerulonephritis","volume":"7","author":"Pawar","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.sder.2006.08.004_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1067\/mjd.2001.114297","article-title":"Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil","volume":"45","author":"Goyal","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/archderm.138.12.1616","article-title":"Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement","volume":"138","author":"Hanjani","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib16","doi-asserted-by":"crossref","unstructured":"Eriksson C, Engstrand S, Sundqvist K, et al: Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64:403-407, 05","DOI":"10.1136\/ard.2004.024182"},{"key":"10.1016\/j.sder.2006.08.004_bib17","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.jaad.2005.11.1090","article-title":"Case reports of etanercept in inflammatory dermatoses","volume":"54","author":"Norman","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0151-9638(05)79503-X","article-title":"Thalidomide in the treatment of chronic discoid lupus erythematosus","volume":"132","author":"Brocard","year":"2005","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.sder.2006.08.004_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.amjmed.2004.04.030","article-title":"Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens","volume":"118","author":"Cuadrado","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.sder.2006.08.004_bib20","first-page":"25","article-title":"B cell-targeted therapy in diseases other than rheumatoid arthritis","volume":"73","author":"Looney","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.sder.2006.08.004_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.rdc.2005.09.007","article-title":"New therapies for systemic lupus erythematosus: cellular targets","volume":"32","author":"Looney","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.sder.2006.08.004_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.sder.2006.08.004_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rdc.2005.11.003","article-title":"Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents","volume":"32","author":"Dooley","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.sder.2006.08.004_bib24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2006.08.004_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2006.08.004_bib27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","article-title":"A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies","volume":"54","author":"Gerami","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib28","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/archderm.1968.01610120030004","article-title":"Histopathology of the skin in dermatomyositis","volume":"97","author":"Janis","year":"1968","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib29","first-page":"64","article-title":"Histopathology of the skin in dermatomyositis: a histopathologic study of 55 cases","volume":"97","author":"Kasper","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0046-8177(96)90132-X","article-title":"The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis","volume":"27","author":"Crowson","year":"1996","journal-title":"Hum Pathol"},{"key":"10.1016\/j.sder.2006.08.004_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/000155502753600894","article-title":"Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies","volume":"82","author":"Parodi","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.sder.2006.08.004_bib32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/ard.2005.040717","article-title":"Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2006.08.004_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/08916930400022681","article-title":"Anti-Mi-2 antibodies","volume":"38","author":"Ghirardello","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.sder.2006.08.004_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archneur.1991.00530130034016","article-title":"The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis","volume":"48","author":"Kissel","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.sder.2006.08.004_bib35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1542\/peds.83.2.278","article-title":"Childhood dermatomyositis: serial microvascular studies","volume":"83","author":"Silver","year":"1989","journal-title":"Pediatrics"},{"key":"10.1016\/j.sder.2006.08.004_bib36","first-page":"1383","article-title":"[Perforating skin ulcers occurring in an adult with dermatomyositis]","volume":"129","author":"Tomb","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.sder.2006.08.004_bib37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1600-0560.1997.tb01458.x","article-title":"The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus","volume":"24","author":"Magro","year":"1997","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.sder.2006.08.004_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-3-2","article-title":"Endothelial cell activation and neovascularization are prominent in dermatomyositis","volume":"3","author":"Nagaraju","year":"2006","journal-title":"J Autoimmune Dis"},{"key":"10.1016\/j.sder.2006.08.004_bib39","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2133.2005.06786.x","article-title":"Evidence for a role of type I interferons in the pathogenesis of dermatomyositis","volume":"153","author":"Wenzel","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib40","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.bor.0000179949.65895.53","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"17","author":"Fathi","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000079903","article-title":"Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients","volume":"209","author":"Garcia-Doval","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.sder.2006.08.004_bib42","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2169\/internalmedicine.44.1197","article-title":"Successful treatment with tacrolimus in a case of refractory dermatomyositis","volume":"44","author":"Mitsui","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.sder.2006.08.004_bib43","first-page":"707","article-title":"Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"23","author":"Ochi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archderm.142.1.65","article-title":"Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis","volume":"142","author":"Edge","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archderm.142.1.70","article-title":"Improvement in dermatomyositis rash associated with the use of antiestrogen medication","volume":"142","author":"Sereda","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","article-title":"Successful treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor alpha: Preliminary observations","volume":"50","author":"Hengstman","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.sder.2006.08.004_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for TNF-inhibitors in the treatment of resistant dermatomyositis and polymyositis","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2006.08.004_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaad.2004.05.044","article-title":"Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis","volume":"52","author":"Nadiminti","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib49","first-page":"1021","article-title":"Rituximab as therapy for refractory polymyositis and dermatomyositis","volume":"33","author":"Noss","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib50","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10654-005-2210-5","article-title":"Systemic sclerosis mortality in the United States: 1979-1998","volume":"20","author":"Krishnan","year":"2005","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.sder.2006.08.004_bib51","first-page":"801","article-title":"Survey of Raynaud\u2019s phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants","volume":"23","author":"Czirjak","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.autrev.2005.09.003","article-title":"Targeted therapy for systemic sclerosis","volume":"5","author":"Steen","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.sder.2006.08.004_bib53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2133.2005.06776.x","article-title":"First case series on the use of imiquimod for morphoea","volume":"153","author":"Dytoc","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib54","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00403-005-0635-z","article-title":"The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?","volume":"297","author":"Yamamoto","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.sder.2006.08.004_bib55","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/art.21497","article-title":"Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells","volume":"54","author":"Distler","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/archderm.138.1.99","article-title":"Treatment of scleroderma","volume":"138","author":"Sapadin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib57","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/art.21899","article-title":"Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis","volume":"54","author":"Kuwana","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib58","first-page":"1488","article-title":"Clinical and serological heterogeneity in patients with anticentromere antibodies","volume":"32","author":"Miyawaki","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/thx.2004.029082","article-title":"Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension","volume":"60","author":"Tamby","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.sder.2006.08.004_bib61","unstructured":"Beretta L, Caronni M, Raimondi M, et al: Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol, in press"},{"key":"10.1016\/j.sder.2006.08.004_bib62","first-page":"813","article-title":"[An up date on pulmonary hypertension related to systemic sclerosis]","volume":"62","author":"Kowal-Bielecka","year":"2005","journal-title":"Przegl Lek"},{"key":"10.1016\/j.sder.2006.08.004_bib63","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.21538","article-title":"Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease","volume":"54","author":"Trad","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib64","first-page":"204","article-title":"Screening for pulmonary hypertension in scleroderma: how and when to look?","volume":"33","author":"Mehta","year":"2006","journal-title":"J Rheumatol"},{"issue":"suppl 1","key":"10.1016\/j.sder.2006.08.004_bib65","first-page":"294","article-title":"Kidney crisis in systemic sclerosis","volume":"50","author":"Lewandowski","year":"2005","journal-title":"Rocz Akad Med Bialymst"},{"key":"10.1016\/j.sder.2006.08.004_bib66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1601-5037.2004.00108.x","article-title":"Factors related to oral hygiene in persons with scleroderma","volume":"3","author":"Poole","year":"2005","journal-title":"Int J Dent Hyg"},{"key":"10.1016\/j.sder.2006.08.004_bib67","first-page":"106","article-title":"Hemodynamic effects of a prostacyclin analog (Prostavasin) in systemic scleroderma patients","volume":"110","author":"Salera","year":"2005","journal-title":"Radiol Med (Torino)"},{"key":"10.1016\/j.sder.2006.08.004_bib68","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib69","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2004.034488","article-title":"Oral sildenafil for the treatment of Raynaud\u2019s phenomenon and digital ulcers secondary to systemic sclerosis","volume":"64","author":"Gore","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2006.08.004_bib70","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.sder.2006.08.004_bib71","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib72","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib73","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.20036","article-title":"Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial","volume":"50","author":"Mayes","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/clim.2000.4920","article-title":"Immune stimulation in scleroderma patients treated with thalidomide","volume":"97","author":"Oliver","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.sder.2006.08.004_bib75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/S0049-0172(03)00135-5","article-title":"High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned","volume":"33","author":"Clements","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib76","doi-asserted-by":"crossref","unstructured":"Jinnin M, Ihn H, Asano Y, et al: Effect of D-penicillamine on pulmonary fibrosis in patients with systemic sclerosis. Ann Rheum Dis 62:1019-1020, 03","DOI":"10.1136\/ard.62.10.1019"},{"key":"10.1016\/j.sder.2006.08.004_bib77","first-page":"206","article-title":"Relaxin (Connetics\/Celltech)","volume":"4","author":"Jones","year":"2001","journal-title":"IDrugs"},{"key":"10.1016\/j.sder.2006.08.004_bib78","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","article-title":"Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial","volume":"42","author":"Black","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.08.004_bib79","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jaad.2003.08.026","article-title":"Low-dose UVA-1 phototherapy in systemic sclerosis: effects on acrosclerosis","volume":"50","author":"Kreuter","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib80","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaad.2004.08.047","article-title":"Narrowband UVB phototherapy in skin conditions beyond psoriasis","volume":"52","author":"Gambichler","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib81","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2005.11.1063","article-title":"A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma","volume":"54","author":"Kreuter","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib82","doi-asserted-by":"crossref","DOI":"10.1007\/s00393-006-0050-7","article-title":"The Scleroderma Assessment Questionnaire (SAQ) A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis","author":"Ostojic","year":"2006","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib83","first-page":"61","article-title":"Bosentan in pulmonary arterial hypertension secondary to scleroderma","volume":"33","author":"Joglekar","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2006.08.004_bib84","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/17402520500233437","article-title":"New therapeutic strategies for systemic sclerosis\u2014a critical analysis of the literature","volume":"12","author":"Zandman-Goddard","year":"2005","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.sder.2006.08.004_bib85","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","article-title":"Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease","volume":"45","author":"Liossis","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.sder.2006.08.004_bib86","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2230.2004.01693.x","article-title":"Combining PUVA therapy with systemic immunosuppression to treat progressive diffuse morphoea","volume":"30","author":"Rose","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.sder.2006.08.004_bib87","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2036.2006.02804.x","article-title":"Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma)","volume":"23","author":"Sallam","year":"2006","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Seminars in Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562906000691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562906000691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scmsjournal.com\/wp-content\/uploads\/2016\/08\/v25i4-Costner.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:35:10Z","timestamp":1707438910000},"score":1,"resource":{"primary":{"URL":"http:\/\/scmsjournal.com\/article\/buy_now\/?id=424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S1085562906000691"],"URL":"https:\/\/doi.org\/10.1016\/j.sder.2006.08.004","relation":{},"ISSN":["1085-5629"],"issn-type":[{"value":"1085-5629","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}